MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2018 International Congress

    Multi-modal retention in a phase III clinical trial in early Parkinson disease (STEADY-PD III)

    B. Greco, R. Holloway, K. Hodgeman, S. Henderson, C. Tarolli, K. Biglan, T. Simuni (Rochester, NY, USA)

    Objective: To evaluate novel retention strategies in an ongoing phase 3 clinical trial in individuals with Parkinson disease (PD). Adequate participant retention is a significant…
  • 2018 International Congress

    Longitudinal observational study on late onset Parkinson’s disease over a decade

    S. Raha, L. Ebenezer (Bridgend, United Kingdom)

    Objective: 1. To analyse the outcome of Late onset Parkinson’s disease over ten year period. 2. To look for any relationship between Initial cognition to…
  • 2018 International Congress

    Determinants of absence of dyskinesia in Parkinson’s disease patients with treatment beyond 10 years

    R. Ou, Y. Wu, Q. Wei, X. Yuan, Y. Hou, H. Liu, L. Zhang, Y. Chen, B. Cao, X. Chen, H. Shang (Chengdu, China)

    Objective: This study aims to explore the determinants for absence of dyskinesia in patients with Parkinson’s disease (PD) based on a large cohort of Chinese…
  • 2018 International Congress

    Contribution of ATP-sensitive potassium channels in the subthalamic nucleus neurons towards Parkinson’s disease

    C. Mahapatra, R. Manchanda (Mumbai, India)

    Objective: This study describe a quantitative investigation to explore the modulating effects of the ATP-dependent Potassium channel (KATP) ion channel conductance on spike patterns in…
  • 2018 International Congress

    Novel COMT inhibitor opicapone shows sustained inhibition and improved L-DOPA availability in monkeys

    T. Kitajima, M. Bonifácio, P. Moser, P. Soares-da-Silva, M. Tanaka (Osaka, Japan)

    Objective: To evaluate the effect of repeated OPC treatments, COMT inhibition versus plasma opicapone level, dose response of COMT inhibition, and systematic and central bioavailability…
  • 2018 International Congress

    Clinical characterization of Pramipexole induced edema and skin reaction in Parkinson’s Disease (PD) after one year of follow up

    E. Urrea-Mendoza, N. Rincon, F. Revilla (Greenville, SC, USA)

    Objective: We report four patients with PD treated several years with irregular and progressively higher doses of pramipexole who presented with extensive chronic bilateral lower…
  • 2018 International Congress

    Effect of dopamine agonists versus levodopa as initial treatment in Parkinson’s Disease

    J. Chen, J. Hong, L. Chunfeng (Suzhou, China)

    Objective: We evaluated the efficacy of different starting drugs in the treatment of Parkinson's disease (PD), in order to further explore the initial therapy of…
  • 2018 International Congress

    Patient and Provider Experiences and Attitudes toward Rytary

    S. Horn, D. Coughlin, J. Chou, F. Wang, M. Stacy, R. Dolhun, C. Kopil, N. Amondikar, A. Deik, H. Sarva (Philadelphia, PA, USA)

    Objective: To survey Parkinson’s disease (PD) patients and providers about their experiences using Rytary, an oral extended release carbidopa/levodopa capsule (ER C/L). Background: ER C/L…
  • 2018 International Congress

    Five Year Outcomes of a Prospective, Multicenter Trial Evaluating Deep Brain Stimulation with a New Multiple Source, Constant Current Rechargeable System in Parkinson’s Disease

    L. Timmermann, R. Jain, N. Van Dyck, L. Chen, T. Brücke, F. Siejo, E. Suarez-San Martin, V. Visser-Vandewalle, M. Barbe, S. Gill, A. Whone, M. Porta, D. Servello, F. Alesch (Köln, Germany)

    Objective: To evaluate the long term follow up of patients in the VANTAGE Study that employed a Deep Brain Stimulation (DBS) system with multiple independent…
  • 2018 International Congress

    Intranasal Delivery of Bromocriptine loaded Lipid Nano Carriers for Enhanced Brain Delivery in Parkinson’s disease

    S. V G, P. Vavia (Mumbai, India)

    Objective: The objective of this research work is to develop a lipid nanocarrier system of Bromocriptine and evaluate its increased efficacy in the management of…
  • « Previous Page
  • 1
  • …
  • 125
  • 126
  • 127
  • 128
  • 129
  • …
  • 177
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley